PL3541784T3 - Nowe pochodne azetydyny użyteczne jako modulatory korowego nuroprzekaźnictwa katecholaminergicznego - Google Patents
Nowe pochodne azetydyny użyteczne jako modulatory korowego nuroprzekaźnictwa katecholaminergicznegoInfo
- Publication number
- PL3541784T3 PL3541784T3 PL17807779.8T PL17807779T PL3541784T3 PL 3541784 T3 PL3541784 T3 PL 3541784T3 PL 17807779 T PL17807779 T PL 17807779T PL 3541784 T3 PL3541784 T3 PL 3541784T3
- Authority
- PL
- Poland
- Prior art keywords
- modulators
- derivatives useful
- azetidine derivatives
- novel azetidine
- cortical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16199545 | 2016-11-18 | ||
| PCT/EP2017/079666 WO2018091687A1 (en) | 2016-11-18 | 2017-11-17 | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3541784T3 true PL3541784T3 (pl) | 2024-03-11 |
Family
ID=57348567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17807779.8T PL3541784T3 (pl) | 2016-11-18 | 2017-11-17 | Nowe pochodne azetydyny użyteczne jako modulatory korowego nuroprzekaźnictwa katecholaminergicznego |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10875829B1 (https=) |
| EP (1) | EP3541784B1 (https=) |
| JP (1) | JP6990702B2 (https=) |
| CN (1) | CN109963834B (https=) |
| DK (1) | DK3541784T5 (https=) |
| ES (1) | ES2962865T3 (https=) |
| FI (1) | FI3541784T3 (https=) |
| PL (1) | PL3541784T3 (https=) |
| PT (1) | PT3541784T (https=) |
| WO (1) | WO2018091687A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112198237B (zh) * | 2020-05-28 | 2021-08-06 | 扬子江药业集团广州海瑞药业有限公司 | 一种盐酸奈康唑杂质检测控制分析方法 |
| KR20260033016A (ko) | 2023-07-06 | 2026-03-10 | 인터그레이티브 리서치 래버러토리즈 스웨덴 에이비 | 병리적 무관심의 치료 및/또는 예방에 사용하기 위한 3-(2,3-디플루오로페녹시)아제티딘 또는 이의 약제학적으로 허용되는 염 |
| CN121548563A (zh) | 2023-07-06 | 2026-02-17 | 综合研究实验室瑞典股份公司 | 3-(2,3-二氟苯氧基)氮杂环丁烷的药学上可接受的盐及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004113297A2 (en) * | 2003-06-24 | 2004-12-29 | Neurosearch A/S | Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| AP2007004047A0 (en) | 2005-01-20 | 2007-06-30 | Pfizer Ltd | Substituted triazole derivatives as oxtocin antagonists |
| WO2007148185A2 (en) | 2006-06-21 | 2007-12-27 | Pfizer Products Inc. | Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors |
| WO2010022055A2 (en) | 2008-08-20 | 2010-02-25 | Amgen Inc. | Inhibitors of voltage-gated sodium channels |
| CA2744308C (en) | 2008-11-24 | 2017-05-30 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission |
| MX2011005034A (es) | 2008-11-24 | 2011-06-16 | Nsab Af Neurosearch Sweden Ab | Nuevos derivados de 3-fenil-azetidina utiles como moduladores de la neurotransmision catecolaminergica cortical. |
| EP2389374A1 (en) | 2009-01-20 | 2011-11-30 | Pfizer Inc. | Substituted pyrazinone amides |
| TWI404721B (zh) * | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2011103196A1 (en) | 2010-02-17 | 2011-08-25 | Amgen Inc. | Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain |
| CA2836851C (en) | 2011-06-07 | 2016-06-21 | Christopher J. Helal | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| KR101273566B1 (ko) | 2011-09-05 | 2013-06-11 | 한국과학기술연구원 | 신규한 아제티딘 유도체 및 이를 함유하는 항우울제 조성물 |
| BR112014018199A8 (pt) * | 2012-01-26 | 2021-03-02 | H Lundbeck As | inibidores da pde9 com cadeia principal imidazo triazinona, composição farmacêutica que os compreende, uso dos referidos inibidores e processo para sua preparação |
| RU2017107521A (ru) | 2014-08-27 | 2018-10-01 | Ф. Хоффманн-Ля Рош Аг | Замещенные производные азетидина в качестве лигандов рецепторов следовых аминов taar |
| EP3215500A1 (en) * | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Substituted azetidinyl compounds as glyt1 inhibitors |
| PT3297987T (pt) * | 2015-05-20 | 2019-06-19 | Integrative Res Laboratories Sweden Ab | Novos derivados de azetidina úteis como moduladores da neurotransmissão catecolaminérgica cortical |
| CN108026030B (zh) | 2015-09-18 | 2020-10-09 | 正大天晴药业集团股份有限公司 | 一种氘代化合物的制备方法 |
| TWI752098B (zh) * | 2016-10-10 | 2022-01-11 | 美商亞雷生物製藥股份有限公司 | 作為ret激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物 |
-
2017
- 2017-11-17 EP EP17807779.8A patent/EP3541784B1/en active Active
- 2017-11-17 FI FIEP17807779.8T patent/FI3541784T3/fi active
- 2017-11-17 DK DK17807779.8T patent/DK3541784T5/da active
- 2017-11-17 WO PCT/EP2017/079666 patent/WO2018091687A1/en not_active Ceased
- 2017-11-17 US US16/461,086 patent/US10875829B1/en active Active
- 2017-11-17 ES ES17807779T patent/ES2962865T3/es active Active
- 2017-11-17 CN CN201780069687.6A patent/CN109963834B/zh active Active
- 2017-11-17 PL PL17807779.8T patent/PL3541784T3/pl unknown
- 2017-11-17 JP JP2019525851A patent/JP6990702B2/ja active Active
- 2017-11-17 PT PT178077798T patent/PT3541784T/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018091687A1 (en) | 2018-05-24 |
| JP2019535715A (ja) | 2019-12-12 |
| US10875829B1 (en) | 2020-12-29 |
| CN109963834A (zh) | 2019-07-02 |
| DK3541784T3 (en) | 2023-10-23 |
| FI3541784T3 (fi) | 2023-10-02 |
| EP3541784B1 (en) | 2023-09-13 |
| ES2962865T3 (es) | 2024-03-21 |
| EP3541784A1 (en) | 2019-09-25 |
| CN109963834B (zh) | 2023-04-14 |
| PT3541784T (pt) | 2023-11-22 |
| DK3541784T5 (da) | 2024-09-16 |
| JP6990702B2 (ja) | 2022-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUS2500016I1 (hu) | Diaril-makrociklusok mint proteinkináz-modulátorok | |
| IL272888B1 (en) | Uses of piperidinyl-indole derivatives | |
| ZA201802150B (en) | Compounds useful as modulators of trpm8 | |
| EP3408268B8 (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| EP3230956A4 (en) | Augmentation of stop-motion content | |
| IL252554A0 (en) | A history of mutated 2-anilinopyrimidines as egfr modulators | |
| IL304618A (en) | Modulators of pcsk9 expression | |
| IL267993A (en) | Bicyclic bis-heteroaryl derivatives as modulators of protein aggregation | |
| SMT202100551T1 (it) | Derivati di sobetirome | |
| EP3180347A4 (en) | Synthesis of cephalosporin compounds | |
| IL273237A (en) | Novel heterocyclic compounds as MGLUR7 modulators | |
| DK3541784T3 (en) | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | |
| GB201409783D0 (en) | Phthalimide derivatives as modulators of WNT pathway | |
| ZA201707936B (en) | Novel azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission | |
| HK40001214A (en) | Benzimidazole derivatives as modulators of ror-gamma | |
| AU2015904123A0 (en) | Augmentation of connective tissue | |
| AU2015903565A0 (en) | Formation of bone | |
| AU2014903769A0 (en) | Brachial effects of infarcts |